Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageNeXT Personal Dx is a tumor-informed liquid biopsy test for the detection of minimal residual disease ("MRD") and recurrence monitoring. We believe NeXT Personal Dx, which was introduced in the fourth quarter of 2023, is the first ultrasensitive test on the market to detect MRD and monitor therapy response in patients with solid tumor cancers. NeXT Personal Dx has been shown to potentially detect cancer recurrence ahead of traditional imaging and is designed to aid decision making throughout a patient's cancer journey.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Personalis, Inc. (PSNL) reported revenue of $15M in Q1 2026 (quarter ended March 31, 2026), down 25% from the same quarter a year earlier. That came with a gross margin of 1.8% and net loss of $30M. For the full year FY2025, revenue was $70M (−18% year on year) and net income −$81M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #20 of 29 by Smart Score